There has been an agreement between QED Therapeutics and Foundation Medicine regarding the development of a companion diagnostic for infigratinib, an inhibitor of the FGFR1-3 selective tyrosine kinase, in patients with cholangiocarcinoma.. A companion diagnostic, which will identify activating FGFR2 fusions, is expected to be incorporated into FoundationOne®CDx, Foundation Medicine's FDA-approved comprehensive genomic profiling (CGP) assay that includes multiple companion diagnostics, as part of FoundationOne®CDx, Foundation Medicine's comprehensive genomic profiling (CGP) test for all solid tumors.
A companion diagnostic, which will identify activating FGFR2 fusions, is expected to be incorporated into FoundationOne®CDx, Foundation Medicine's FDA-approved comprehensive genomic profiling (CGP) assay that includes multiple companion diagnostics, as part of FoundationOne®CDx, Foundation Medicine's comprehensive genomic profiling (CGP) test for all solid tumors.
"While targeted therapies have transformed the treatment landscape for multiple cancers, such as lung cancer, cholangiocarcinoma has not yet benefited from these advances," says Susan Moran, M.D., M.S.C.E., chief medical officer of QED Therapeutics. It has been demonstrated that infigratinib has promising potential in FGFR2 fusion-driven cholangiocarcinoma, so it is crucial for physicians to have a companion diagnostic in order to identify patients who are potentially suitable for treatment.
A brief description of QED Therapeutics QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotech company focused on providing precision medicine to patients suffering from diseases triggered by FGFR. Our lead investigational candidate is infigratinib (BGJ398), an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown significant clinical activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions as well as advanced urothelial carcinoma with FGFR3 genomic changes.. The company is also testing infigratinib for the treatment of achondroplasia and other skeletal dysplasias in preclinical studies. It is our intention to conduct further clinical trials to evaluate infigratinib in additional FGFR-driven tumor types and rare disorders in the future
It is our intention to conduct further clinical trials to evaluate infigratinib in additional FGFR-driven tumor types and rare disorders in the future
QED Therapeutics is the source of this information
Get PRN's top stories and curated news delivered to your inbox every week by signing up for PRN's newsletter!

Source prnewswire